HOME >> BIOLOGY >> NEWS
Lawrence Livermore Lab, UC Davis Cancer Center ink alliance to develop integrated cancer program

Collaboration is latest initiative between the national lab and UC Davis Health System

SACRAMENTO, Calif. - Lawrence Livermore National Laboratory and the UC Davis Cancer Center have agreed to collaborate on an integrated cancer program that will bring together the advanced biomedical technologies and scientists of the national laboratory with basic science researchers and faculty oncologists from UC Davis.

"This agreement signifies an institutional commitment to bringing together researchers from two different cultures: the scientists of Lawrence Livermore with the patient-centered clinical researchers of the cancer center," said Ralph deVere White, director of the UC Davis Cancer Center. "Together we can create a multidisciplinary tour de force focused on revolutionary - as opposed to evolutionary - advances in treating cancer."

"We will be combining our basic science program with the basic science program of the UC Davis Health System to bring about better methods of prevention and treatment for cancer patients," added Jim Felton, leader of the Molecular and Structural Biology Division at Lawrence Livermore. "We are very excited about the potential of this collaboration."

Scientists from the laboratory's Biology and Biotechnology Research Program, Physics and Advanced Technologies Program, Energy and Environment Program and Medical Technology Program will collaborate with UC Davis Cancer Center researchers in cancer genetics, molecular pharmacology and new drug development in investigating new approaches to cancer.

Ongoing basic science research in toxicology, carcinogenesis mutation, animal sciences and DNA repair at UC Davis will be an integral part of this collaboration as well.

Specific projects under discussion include:
* Studies of phytochemicals that may affect the development of cancer. Using high-powered computers and imaging devices, Lawrence Livermore scientists are able to detect microscopic changes
'"/>

Contact: Stephen Wampler
wampler1@llnl.gov
925-423-3107
DOE/Lawrence Livermore National Laboratory
1-Nov-2000


Page: 1 2 3

Related biology news :

1. Secretary of Energy announces seven E.O. Lawrence Award Winners
2. Seven E.O. Lawrence Award winners named
3. Lawrence Livermore research team finds unique DNA signatures to improve anthrax detection
4. UC Davis and Lawrence Livermore National Laboratory seek industry partners to develop new bio and medical technology products
5. Howard Hughes Medical Institute funds biomedical facilities at Lawrence Berkeley National Lab
6. Livermore research in accelerator mass spectrometry highlighted at ACS meeting
7. Livermore & NIH scientists create technique to examine behavior of proteins at single molecule level
8. Livermore researchers apply combat simulation technology to homeland security
9. NNSAs Livermore Lab partners with cities and counties to track biological, chemical releases
10. Livermore Lab hosts conference on Bioterrorism for the Courts
11. Livermore research team wins distinguished Department of Energy award for development of miniature glucose sensor for diabetes patients

Post Your Comments:
(Date:4/20/2015)... The announcement comes as demand for fire ... Ireland,s foremost records management company, has ... an impressive track record of clients within the first 12 ... management sector in Dubai . As a ... employ a further eight staff members at its Irish headquarters. ...
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
(Date:4/13/2015)... April 13, 2015 According ... "Global Biometrics Market Forecast & Opportunities, 2020", the global ... of around 14% till 2020. The biometrics market ... scale implementation and review of biometric management systems. ... new products with greater efficiency, are resulting in ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
(Date:5/26/2015)... Pharmaco-Kinesis Corporation (PKC) announced today that its ... on the Beach in Santa Monica, CA ... Company,s innovative Metronomic Biofeedback Pump (MBP), a fully smart ... time to a target site of the human body ... in real-time.  ...
(Date:5/26/2015)... JERUSALEM , May 26, 2015 ... http://www.oramed.com ), a clinical-stage pharmaceutical company focused on the ... it has submitted the study protocol for the company,s ... to the U.S. Food and Drug Administration (FDA). The ... Drug (IND) application. The Phase IIb study ...
(Date:5/26/2015)... Just the characterization of being a new breakthrough ... not guarantee immediate acceptance. In particular, a new ... failures is often met with significant skepticism. The ... that is often an unappreciated aspect of scientific innovation. ... has found that building acceptance of its new ...
(Date:5/22/2015)... , May 22, 2015  Actavis plc (NYSE: ... U.S. Court of Appeals for the Second Circuit has ... injunction requiring the Company to continue distribution of NAMENDA ... - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO   "While we ... ruling, we intend to continue our strong efforts to ...
Breaking Biology Technology:Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 2Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 4Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 5Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 3In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 2In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells 3Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 2Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 3Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 4Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 5Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 6Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 7Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 8
Cached News: